论文部分内容阅读
必须联合化疗用单药虽可达CR,但不能治愈急白。联合用药有相加或协同作用,减少耐药株发生率。已证明几个重要的联合有相加作用。ALL:强的松加下列之一。MTX、6MP、VCR、阿霉素;蒽环类加Ara-C;MTX 与L-ASP 序贯;VR-16加Ara-C;MTX 加thiopurine;MTX 加Ara-C。ANLL:蒽环类加Ara-C;胺苯吖啶加Ara-C;VP-16加Ara-C;米妥蒽醌加VP-16。在治疗几疗程后,耐药性迅速出现,应序贯给药,每个方案用3至4次,如果ANLL 象ALL 一样有可替换的方案,治愈率将会提高。增加剂量强度复发的白血病能耐受缓解期剂量的几倍药量。米妥蒽醌、Ara-C、VP-16的剂量可逐渐加大。强化疗并不能治愈复发的白血病。在初治时,诱导化疗应尽可能强烈。对ALL 可序贯用有效
A single drug that must be combined with chemotherapy, although it can reach CR, cannot cure acute whiteness. The combined use of drugs has additive or synergistic effects to reduce the incidence of drug-resistant strains. Several important combinations have been shown to have an additive effect. ALL: Prednisone plus one of the following. MTX, 6MP, VCR, doxorubicin; anthracycline plus Ara-C; MTX and L-ASP sequential; VR-16 plus Ara-C; MTX plus thiopurine; MTX plus Ara-C. ANLL: Anthracycline plus Ara-C; Aminopteridine plus Ara-C; VP-16 plus Ara-C; Mitutolu plus VP-16. After several courses of treatment, drug resistance occurs rapidly and should be administered sequentially, with 3 to 4 cycles per protocol. If ANLL has alternatives like ALL, the cure rate will increase. Increasing the dose intensity of relapsed leukemia can tolerate several times the dose of remission dose. The doses of Metoprolol, Ara-C and VP-16 can be gradually increased. Intensive chemotherapy does not cure relapsed leukemia. In the initial treatment, induction chemotherapy should be as strong as possible. Valid for ALL sequential use